Skip to content

Initial Cost Estimates of H.R. 3; Price Negotiation, Inflation Rebates Analyzed

Initial Cost Estimates of H.R. 3; Price Negotiation, Inflation Rebates Analyzed

The Congressional Budget Office (CBO) released a preliminary cost estimate of title I of the Lower Drug Costs Now Act of 2019 (H.R. 3) regarding price negotiation of certain prescription drugs in Medicare Part D. CBO estimates that enacting title I would reduce federal spending for Medicare by $345 billion over the 2023-2029 period. A summary follows below. Title I… (Llamas) #Insurance Reform, #Medicare Part D, #Prescription Drugs

CONTACT US

Improving Health is Our Policy